Clinical Trials - VXRT

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06944717A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years OldACTIVE_NOT_RECRUITINGPHASE12025-03-032026-05-012026-05-01
NCT06672055A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionRECRUITINGPHASE22024-10-082026-112026-11
NCT05626803A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersCOMPLETEDPHASE22023-01-262023-10-162023-10-16
NCT05213728A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult VolunteersCOMPLETEDPHASE12022-01-242022-02-242022-02-01
NCT05212168Norovirus Challenge StudyCOMPLETEDPHASE1, PHASE22021-12-272023-10-272023-04-13
NCT05067933A Ph 2 Trial With an Oral Tableted COVID-19 VaccineTERMINATEDPHASE22021-10-222023-05-092022-06-10
NCT04875676Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus VaccinesCOMPLETEDPHASE1, PHASE22021-04-302022-02-162021-10-30
NCT04854746Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus VaccineCOMPLETEDPHASE12021-04-262022-01-042022-01-04
NCT04563702Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of SubjectsCOMPLETEDPHASE12020-09-212021-10-102021-10-10
NCT03897309Safety & Immunogenicity Study of Ad5 Based Oral Norovirus VaccinesCOMPLETEDPHASE12019-03-202021-04-012021-01-15
NCT03125473Dose-Optimization Trial of VXA-G1.1-NN in Healthy VolunteersCOMPLETEDPHASE12017-04-072018-05-062017-07-01
NCT03121339Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy AdultsCOMPLETEDPHASE12017-03-312018-04-032017-05-05
NCT02918006A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu VaccineCOMPLETEDPHASE22016-08-312018-01-192017-08-08
NCT02868073Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus VaccineCOMPLETEDPHASE12016-07-292017-10-012016-10-05
NCT02830932Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)COMPLETEDPHASE12016-06-222017-09-202016-09-16
NCT02877264A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy VolunteersCOMPLETEDPHASE12016-062016-08
NCT02718937Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge StudyCOMPLETEDPHASE22016-032016-122016-12
NCT02724254A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma PatientsCOMPLETEDPHASE22016-012018-072018-05
NCT02668367Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy VolunteersCOMPLETEDPHASE12015-112016-022016-02
NCT02547792Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy AdultsCOMPLETEDPHASE12015-10-202016-11-212016-11-21
NCT02558413Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy VolunteersCOMPLETEDPHASE12015-082015-122015-12
NCT02367313A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus InfectionCOMPLETEDPHASE22015-022016-122016-12
NCT02204501A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female VolunteersCOMPLETEDPHASE12014-052014-062014-06
NCT02101866A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy VolunteersCOMPLETEDPHASE12014-032014-062014-05
NCT02014649Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With InfluenzaTERMINATEDPHASE1, PHASE22013-112014-052014-04
NCT02022761Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic AsthmaCOMPLETEDPHASE12013-102014-022013-10
NCT01793883Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With InfluenzaCOMPLETEDPHASE22013-052014-052014-05
NCT01761123Immunogenicity of Seasonal Influenza by Delivery Directly to IleumCOMPLETEDPHASE12013-012014-102014-10
NCT01688297Safety Study of an Oral Vaccine to Prevent Seasonal InfluenzaCOMPLETEDPHASE12012-092015-042014-05
NCT01698060Immunogenicity of ND1.1 by Delivery Directly to the IleumCOMPLETEDPHASE12012-092013-112013-11
NCT01532102Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital WartsCOMPLETEDPHASE1, PHASE22012-02-282013-05-062013-05-06
NCT01335347Safety Study of an Oral Vaccine to Prevent Avian InfluenzaCOMPLETEDPHASE12011-042012-092012-08
NCT01175226A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus InfectionCOMPLETEDPHASE22010-082012-032012-03
NCT00995826Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958COMPLETEDPHASE12009-042009-112009-09
NCT00657111CS-8958 Single Inhaled Dose in ElderlyCOMPLETEDPHASE12008-042009-102009-10
NCT00504907Safety Study of Oral BTA9881 to Treat RSV InfectionCOMPLETEDPHASE12007-072008-122008-12
NCT00311714Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958COMPLETEDPHASE12007-042007-12
NCT03024177A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus InfectionWITHDRAWNPHASE22017-04